Eli Lilly and Company stock price

Eli Lilly and Company latest news:


  • 02/23/2018 15:05:28

    BRIEF-Eli Lilly Says CEO David Ricks' FY 2017 Total Compensation Was $15.8 Mln

    Eli Lilly And Co(LLY): * ELI LILLY AND CO SAYS CHAIRMAN AND CEO DAVID RICKS' FY 2017 TOTAL COMPENSATION WAS $15.8 MILLION. * ELI LILLY AND CO SAYS CEO DAVID RICKS' FY 2017 TOTAL COMPENSATION INCLUDED $10.2 MILLION OF STOCK AWARDS Source text: Further company coverage:

  • 01/31/2018 06:03:56

    Drugmaker Eli Lilly beats estimates, raises 2018 profit forecast

    Jan 31 (Reuters) - Eli Lilly and Co reported a bigger-than-expected quarterly profit on Wednesday, helped by demand for new diabetes and psoriasis treatments, while raising its adjusted earnings forecast for 2018 due to U.S. tax changes.

  • 01/31/2018 05:37:00

    Drugmaker Eli Lilly posts quarterly loss on tax charges

    Eli Lilly and Co reported a quarterly loss, compared with a year-ago profit, as the drugmaker recorded charges largely related to changes to the U.S. tax law.

  • 01/31/2018 05:14:35

    Eli Lilly shares rise after Q4 profit, revenue beats, upbeat outlook

    Eli Lilly & Co. shares rose 0.6% in premarket trade Wednesday after the company reported fourth-quarter profit and revenue beats and an upbeat outlook. The company reported a loss of $1.66 billion, or a loss of $1.58 per share, after earnings of $771.8 million, or 73 cents per share. Adjusted earnings-per-share were $1.14, compared with the FactSet consensus of $1.07. Revenue rose to $6.16 billion from $5.76 billion, compared with the FactSet consensus of $5.94 billion. The latest results include higher volume for new drugs like Trulicity, Basaglar, Taltz, Jardiance, Lartuvo and Verzenio and higher prices for several pharmaceutical products. The company also said it saw decreased volume due to competition for Strattera and Effient, lower demand for Cialis and food animal products and lower prices for Humalog. Eli Lilly now expects 2018 EPS of $4.39 to $4.49, compared with the FactSet consensus of $4.18, and 2018 adjusted EPS of $4.81 to $4.91, compared with the FactSet consensus of $4.65; the company said the revisions reflect the expected impact of corporate tax reform. Sales of Humalog, Alimta, Forteo, Humulin, Cymbalta, Erbitux, Zyprexa, Effient, Trulicity, Lartruvo and Cyramza beat FactSet expectations, while sales of Cialis, Strattera, Taltz, Jardiance, Basaglar and Portrazza missed expectations. Eli Lilly shares have risen 5.1% over the last three months, compared with a 9.6% rise in the S&P 500 and a 11.6% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 01/24/2018 13:08:43

    Ex-Eli Lilly executive Alex Azar confirmed as HHS boss

    Alex Azar, the former president of Eli Lilly USA, was confirmed by the Senate on Wednesday to become secretary of the Health and Human Services Department. He replaces Tom Price, who resigned last year after a controversy over his use of private plans for government travel. Azar will lead efforts by the Trump administration to dismantle Obamacare. He's also vowed to boost efforts to lower U.S. drug prices, though critics are skeptical because of his close ties to the pharmaceutical industry. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 01/22/2018 06:07:05

    BRIEF-Elanco Animal Health Announces U.S. FDA Approval Of Credelio To Treat Ticks And Fleas

    Eli Lilly And Co(LLY): * ELANCO ANIMAL HEALTH ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL OF CREDELIO® TO TREAT AND PROTECT AGAINST TICKS AND FLEAS Source text for Eikon: Further company coverage:

  • 12/14/2017 09:52:37

    BRIEF-NSAV Subsidiary Signs Agreement With Eli Lilly

    Net Savings Link(NSAV): * NSAV SUBSIDIARY SIGNS MAJOR AGREEMENT WITH ELI LILLY AND COMPANY. * NET SAVINGS LINK SAYS VSRI WILL PROVIDE ELI LILLY WITH ASSESSMENT OF CVD AMONG NEWLY DIAGNOSED DIABETES PATIENTS AT INCREASED RISK OF CVD IN CHINA Source text for Eikon: Further company coverage:

  • 12/11/2017 13:36:55

    Eli Lilly hikes dividend by 8%

    Eli Lilly and Co. said Monday its board approved an 8% hike in its quarterly dividend. The drugmaker said it will pay a 56.25 cents a share dividend in the first quarter to shareholders of record as of Feb. 15 on March 9. Eli Lilly shares rose 0.2% to $86.64 in recent trading.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/11/2017 12:04:25

    FDA OKs Sanofi's follow-on biologic of Lilly's diabetes drug Humalog

    The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's (LLY) fast-acting insulin, Humalog. Admelog, generally taken just before meals, was approved for use in children older than three and adults with type 1 diabetes, as well as adults with type 2 diabetes.

  • 12/11/2017 12:04:06

    UPDATE 1-FDA OKs Sanofi's follow-on biologic of Lilly's diabetes drug Humalog

    Dec 11 (Reuters) - The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog.

  • 12/11/2017 11:13:52

    FDA clears Sanofi's follow-on diabetes biologic of Lilly's Humalog

    Dec 11 (Reuters) - The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog.

  • More trends:

    Ellie MaeELLI | Ellington Financial LLCEFC | Ellington Residential Mortgage REITEARN | Embotelladora Andina S.A.AKO.A | Embotelladora Andina S.A.AKO.B | Embraer-Empresa Brasileira de AeronauticaERJ | EMC CorporationEMC | EMCOR GroupEME | Emerge Energy Services LPEMES | Emergent BiosolutionsEBS |